Mitsubishi Chemical Group named Bain Capital as the preferred bidder for its pharmaceutical subsidiary, Tanabe Mitsubishi Pharma.
The potential transaction, valued at over $3bn, is part of Mitsubishi Chemical’s ongoing efforts to streamline its portfolio.
While Mitsubishi Chemical has not confirmed details of the deal, it stated, “We are continuously reviewing the ideal business portfolio of the entire group, including the Pharma business, with all options, including divestiture, under consideration.”
Japanese media reported that the sale could exceed JPY500bn ($3.2bn), but Mitsubishi Chemical clarified that the report was not issued by the company. Bain Capital, which has emerged as the frontrunner, declined to comment.
Previously, Reuters reported that Bain Capital and Blackstone were among the final bidders for Tanabe Mitsubishi Pharma, with the deal estimated to be worth between $3bn and $3.5bn. The negotiations represent a significant step in Mitsubishi Chemical’s strategy to optimise its portfolio and focus on core business areas.
This deal underscores private equity’s growing interest in the healthcare sector, as firms target opportunities in pharmaceutical and biotech industries amid increased global demand for innovation in medicine.
Source: Private Equity Wire
Can’t stop reading? Read more
Blackstone taps bond market as private credit BDCs end issuance drought
Blackstone taps bond market as private credit BDCs end issuance drought Blackstone's private...
EQT raises the stakes with revised $12.3bn bid for Intertek
EQT raises the stakes with revised $12.3bn bid for Intertek EQT has tabled an improved takeover...
Temasek’s Azalea bets on evergreen structure to democratise private equity access
Temasek's Azalea bets on evergreen structure to democratise private equity access Azalea, a unit...